Bactana is a socially impactful company formed as a spin-off from Cornell University and currently part of the PEI Emergence Bioscience program. Bactana has patented the use of a select group of anaerobic bacteria strains that have demonstrated multiple health benefits for companion animals, livestock, and potentially humans. Their lead technology manipulates the microbial ecology of animals to enhance the interaction of an animal’s microbiome with its immune system & metabolism. Bactana is seeking an experienced Senior Microbiology Director with an entrepreneurial spirit to join their research team to support the discovery process and help scale the fermentation and production process as they prepare for product launch. This position will be based in Charlottetown, Prince Edward Island. Link to job posting here.
Emergence Client Advanced Extraction Systems will soon have a new manufacturing, R&D and testing facility.
David Campbell, Co-Founder and COO of AESI states, “In order to meet increasing production demand, we are pleased to announce that our new state of the art production facility will be completed in the coming months. The new manufacturing, R&D, and testing facility will allow for increased vertical integration ensuring the highest level of quality that’s expected from an industry leader.” AESI has seen great success in the global hemp and cannabis industries. “This expansion will take us to the next level as we continue to separate ourselves from the competition. The response has been immense on our newest system in the AESI lineup, the 4 x 1000L, and our new production facility will carry us through the next phase of expansion” states David Campbell. Mr. Campbell continues, “AESI continues to be a trailblazer in the industry with projected growth that has attracted international investors expecting to capitalize on the future success of the company”.
Recently AESI made headlines after releasing production capacities for their newest system, the Largest CO2 Supercritical Fluid Extraction System for the Global Hemp & Cannabis Industries. “It’s an exciting time in this emerging industry and our new state of the art facility is just the next step to ensure we maintain our position as an industry leader”.
Advanced Extraction Systems Inc. designs, engineers and fabricates supercritical fluid CO2extraction systems with a specific focus in the medical/recreational marijuana and hemp industries. AESI has assembled a skilled management team and a world-class scientific advisory group with over 75 years of experience in supercritical fluid design and processes. AESI offers the cleanest, most advanced CO2 extraction processes that are leading edge due to the companies ongoing internal focus on research and development. AESI CO2 extraction systems are unique in design, efficiency, and ease of operation. Specifically, AESI systems can be differentiated from the competition in 6 key technical areas; better pump reliability, superior flow rates, superior fractionation, more phase management control, cGMP recipe development, and scalability for future growth.
SOURCE Advanced Extraction Systems
Emergence client Torigen Pharmaceuticals Inc., a startup in companion animal immuno-oncology, announces its founder and chief executive officer, Ashley Kalinauskas, has been honored as the 2019 Entrepreneur of the Year in the Scalable Venture category (under $1 million in sales) by the CT Entrepreneur Awards. Kalinauskas was recognized for her entrepreneurial achievements in 2018 with the company’s first product, an autologous prescription product for dogs and cats that uses the animal’s own tumor cells to create a personalized immunotherapy.
In 2018, Torigen hit several major milestones, including completion of its Series A with a $2.3 million equity raise, and treated nearly 250 companion animals diagnosed with cancer last year. Torigen also was named the 2018 Top Animal Health Innovation at the Kansas City Animal Health Investment Forum and a Million Dollar Women Company. Torigen was nominated for the CT Entrepreneur Awards by the UCONN Technology Incubation Program (TIP), recognized as having high potential for organizational growth.
“I’m extremely proud and humbled to be a part of a remarkable team at Torigen,” said Kalinauskas. “To be considered among this distinguished group of entrepreneurs and companies is a testament to the passion we each feel in our pursuit of life-changing solutions for pets with cancer. Thank you to UCONN TIP and the CT Entrepreneur Event Organizers Consortium for making this award possible.”
The annual CT Entrepreneur Awards identify, recognize and celebrate Connecticut’s leading entrepreneurs, ventures and ecosystem elements that support them. Nominations for the 2019 CT Entrepreneur Awards began in December 2018, and finalists were selected for a 30-day community-voting period from February to March 2019. The winners were announced April 18, 2019.
Cancer is the number-one cause of death in dogs over the age of two, and one in four dogs will be impacted by cancer in their lifetimes. Torigen is offering exciting potential for pets with cancer through its Autologous Prescription Product, which works by stimulating an immune response that targets and destroys the cancer cells specific to the patient.
Experimental autologous cancer vaccines created by Torigen Pharmaceuticals Inc. are regulated by the USDA Center for Veterinary Biologics. For use under supervision/prescription of a licensed veterinarian. Safety and efficacy have not been established.
About Torigen Pharmaceuticals Inc.
Torigen Pharmaceuticals Inc. is focused on delivering affordable companion animal immuno-oncology products. Its initial patented product line utilizes a portion of the pet-patient’s tumor to create a personalized cancer vaccine. With over 10 years of supporting pre-clinical publications, the Torigen team is focused on developing innovative veterinary cancer biologics that allow for the body to recognize foreign tumor–associated antigens and facilitate the reversal of immune senescence. For more information, please visit http://www.torigen.com.
(Source: FARMINGTON, Conn., May 7, 2019 /PRNewswire-PRWeb)
Note: Ashley Kalinauskas, Torigen Pharmaceuticals CEO, will present at VetHealth Global 2019, June 24-26th in Charlottetown, Prince Edward Island.
Here is a summary of the Emergence clients advertising job opportunities this week:
- Dosecann has 10 positions
- Torigen has three positions
- FIGR has five positions
- BioTraceIT has two positions
- Dalriada has five positions
- Chinova Bioworks has two positions
- Bactana has one position
- Center for Aquaculture Technologies has three positions
- Island Abbey Foods has one position
- Noblegen has four positions
- Somru Biosciences has one position
- Soma Detect has five positions
Chinova Bioworks was selected to join 2019 Sephora Accelerate which builds a community of innovative female founders in beauty. Sephora’s site offers some background on the program:
Even in the beauty industry, where most customers are women, female founders are still underrepresented. We saw a unique opportunity to draw from our history of working with beauty entrepreneurs to build a supportive community for women who are in the early stages of developing their businesses. Accelerate is a key initiative of a larger program called Sephora Stands, which aims to use Sephora’s strengths for even greater good in our communities. We hope to build an ecosystem of support for more than 50 women-led beauty businesses by 2020.
Founders will participate in a week-long Bootcamp in San Francisco, May 5-11, and have a follow-up opportunity to pitch to Sephora’s Merchandising and Innovation teams on Demo Day this Fall.
Chinova Bioworks has developed a natural preservative, Chiber Mushroom Extract, to extend shelf life in foods, beverages, cosmetics and personal care items.
New Emergence client, Because Animals, started by two Torontonians, is a company making human grade sustainable, animal-free pet food. Shannon Falconer has a PhD in microbial chemical biology and worked as a postdoctoral fellow at Stanford University. Joshua has worked as a journalist, banker and cat rescuer. He graduated with an MBA from Indiana University’s Kelley School of Business. Because Animals already has a couple of superfood supplements for both dogs and cats, and now they are developing lab-grown meat for pet food. They recently announced a prototype cat treat. They are one of the companies that sees opportunities. Read more here.
On April 23, 2019, all shares in leading aquaculture R&D company The Center for Aquaculture Technologies (CAT), were purchased by Cuna Del Mar LP (CDM), a US-based aquaculture investment fund, for an undisclosed amount from Linnaeus Capital Partners BV.
Dr. John Buchanan, CEO of CAT, commented: “We look forward to working within Cuna del Mar, a fund that clearly sees the potential for growth in the aquaculture industry.”
Robert Orr, Managing Director of Cuna Del Mar, added “Cuna del Mar is very pleased to be acquiring the CAT operations in the USA and Canada. CAT has a tremendously talented team of people with unique capabilities, who are dedicated to making a difference for our customers and the industry as a whole. We are excited about the possibilities the future holds for this business.”
CAT currently operates two laboratories: its research hub in San Diego, California, and state-of-the-art wet lab facilities including BSL 3 containment for aquatic animal pathogens, located on Prince Edward Island in Canada. Thanks to the expertise of its team and the unique versatility of its laboratories, CAT is enabling the aquaculture industry to achieve efficient production of through genetic improvement as well as facilitating commercial development of innovative feed and health management products and services.
With Cuna Del Mar, CAT looks forward to working with other companies within the CDM portfolio and to expanding its capacity for conduct of aquaculture contract research and services in support of the global aquaculture industry.
For more information, please contact Debbie Plouffe at email@example.com or at 902-687-1245.
CAT is a member of the Emergence Bio-incubator.
RPS Biologiques Announces Health Canada Approval of SupratectTM; the First Veterinary Health Product Approved for use in Finfish Aquaculture
RPS Biologiques Inc. is pleased to announce the reception of two (2) Notification Numbers from the Health Canada Veterinary Drugs Directorate (VDD) for their Veterinary Health Products (VHP), Supratect-L and Supratect -P. The Notification Numbers indicate approval, allowing for marketing and sale of Supratect in Canada. The use of Supratect has been fully tested for the maintenance of optimal health of fish and fish eggs in finfish species. It consists of natural ingredients that are completely safe and beneficial for the target species. Supratect is the first and only current Natural fish health product to receive approval, in Canada, through the Veterinary Health Products notification program.
The President of RPS Biologiques, Dr. Subrata Chowdhury, says the objective of the company is to become a leader in developing safe, all natural, fish health products for use in the aquaculture sector. Dr. Chowdhury is a molecular biologist with wide experience in the fields of microbiology, virology, immunology and genetics. He notes that RPS Biologiques is continuing to develop additional, unique natural products for use in the animal health sector.
The testing undertaken to validate Supratect was completed, over a three-year period, mainly at the Huntsman Marine Science Centre located in St Andrews, New Brunswick. Established in 1969, Huntsman is a private, not-for-profit research and science based teaching institution whose work is recognized throughout Canada and internationally.
Paul Dick & Associates (PDA), a global consulting company, worked with RPS Biologiques and Health Canada to obtain notification for Supratect via the VHP program. The firm specializes in the development and registration of animal and human health products including veterinary biologics, veterinary drugs, feeds and natural health products.
RPS Biologiques Inc is a privately-owned Canadian company based in Charlottetown, Prince Edward Island and a member of the PEI Bioalliance Emergence Bio-incubator.
Emergence client Dosecann, a PEI-based Licensed Dealer developing a suite of cannabis products across a variety of delivery methods for both the medical and adult use markets, is currently hiring for 12 new positions. Positions include:
- HR Manager
- Analytical Scientist I
- Warehouse Clerk
- HR Manager
- Analytical Scientist II
- Analytical Scientist III
- QC Chemist
- Extraction Technician
- Formulation Scientist
- Packaging Technician
- QA Specialist
- QA Support – Validation/Documentation
See more details on these positions here.
Dosecann has assembled a world-class team housed in a purpose-built, 42,000 sqft. GMP compliant facility that will be the hub for cannabis extraction, product innovation and formulation.
Emergence clients Ethicann Pharmaceuticals, a company that sources pharmaceutical-grade botanically sourced cannaboid oils to formulate ethical drugs has closed a successful initial financing round. Several Canadian and US venture funds and high net worth individuals and entrepreneurs with considerable industry experience are the investors.
One of Ethicann’s recent milestones saw their US subsidiary holding successful Pre-IND meeting with the US Food and Drug Administration to discuss the 505(b)2 requirements for a marketing approval for its first product (CAN-001) to treat chemotherapy-induced nausea and vomiting.
For more details on the company and their latest achievement, click here..